Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice.
| Title: | Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice. |
|---|---|
| Authors: | Gundersen KB; VIRTU research group, Copenhagen Research Centre for Mental Health, Hellerup, Denmark kristina.ballestad.gundersen@regionh.dk.; Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.; Department of Psychology, University of Copenhagen, Copenhagen, Denmark.; Rasmussen AR; Mental Health Center Amager, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark.; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.; Sandström KO; Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.; Albert N; Department of Clinical Medicine, University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark.; Copenhagen Research Centre for Mental Health (CORE), Hellerup, Denmark.; Polari A; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.; Orygen Specialist Program, Parkville, Victoria, Australia.; Ebdrup BH; Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.; Department of Clinical Medicine, University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark.; Nelson B; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.; Orygen, Parkville, Victoria, Australia.; Glenthøj LB; VIRTU research group, Copenhagen Research Centre for Mental Health, Hellerup, Denmark.; Department of Psychology, University of Copenhagen, Copenhagen, Denmark. |
| Source: | BMJ open [BMJ Open] 2023 Nov 17; Vol. 13 (11), pp. e075140. Date of Electronic Publication: 2023 Nov 17. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [London] : BMJ Publishing Group Ltd, 2011- |
| MeSH Terms: | Schizotypal Personality Disorder*/diagnosis ; Schizotypal Personality Disorder*/therapy; Humans ; Systematic Reviews as Topic ; Research Design ; Meta-Analysis as Topic ; Review Literature as Topic |
| Abstract: | Introduction: Schizotypal disorder is associated with a high level of disability at an individual level and high societal costs. However, clinical recommendations for the treatment of schizotypal disorder are scarce and based on limited evidence. This review aims to synthesise the current evidence on treatment for schizotypal disorder making recommendations for clinical practice.; Methods and Analysis: This systematic review protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A systematic literature search will be performed in PsychArticles, Embase, Medline and Cochrane Central Register of Controlled Trials. Additionally, we will search for relevant articles manually. Inclusion criteria are published studies including individuals diagnosed with schizotypal personality disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria, or schizotypal disorder according to International Classification of Diseases (ICD) criteria. We will include interventional studies comprising any pharmacological and non-pharmacological treatment trials for patients with schizotypal disorder, and all relevant outcome measures will be reported. Risk of bias will be assessed by Cochrane risk-of-bias tools. Data will be synthesised using narrative or thematic analysis and, if suitable, through meta-analysis.; Ethics and Dissemination: No original data will be collected as part of this study and ethics approval is, therefore, not applicable. The results will be disseminated through peer-reviewed publication and presented at international scientific meetings. We will aim at submitting the final paper for publication within 4 months of completion of analyses. Furthermore, this systematic review will inform clinicians and researchers on the current state of evidence on treatment for schizotypal disorder. Findings may guide proposals for further research and potentially guide recommendations for clinical practice using the Grading of Recommendations Assessment, Development and Evaluation.; Prospero Registration Number: CRD42022375001.; (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Competing Interests: | Competing interests: BHE has received lecture fees and/or is part of Advisory Boards of Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Otsuka Pharma Scandinavia AB, Takeda Pharmaceutical Company, Boehringer Ingelheim and Lundbeck Pharma A/S. |
| References: | Curr Psychiatry Rep. 2014 Jul;16(7):452. (PMID: 24828284); Lancet Psychiatry. 2021 Nov;8(11):1001-1012. (PMID: 34688345); J Clin Exp Neuropsychol. 2016 Nov;38(9):1050-63. (PMID: 27295077); Eur Arch Psychiatry Clin Neurosci. 2018 Oct;268(7):713-718. (PMID: 28865064); Am J Psychiatry. 1953 Dec;110(6):406-16. (PMID: 13104683); Schizophr Res. 2017 Apr;182:24-30. (PMID: 27760701); J Med Libr Assoc. 2018 Oct;106(4):420-431. (PMID: 30271283); Ann Gen Psychiatry. 2021 Feb 2;20(1):10. (PMID: 33531016); J Clin Epidemiol. 2013 Jul;66(7):719-25. (PMID: 23312392); Am J Psychiatry. 2005 Oct;162(10):1896-903. (PMID: 16199836); Acta Psychiatr Scand. 2021 Jul;144(1):60-71. (PMID: 33650099); Schizophr Bull. 1985;11(4):538-53. (PMID: 3909377); Schizophr Res. 2006 Mar;83(1):29-40. (PMID: 16504481); JAMA Psychiatry. 2021 Sep 1;78(9):970-978. (PMID: 34259821); Encephale. 2021 Jun;47(3):254-262. (PMID: 33648750); BMJ. 2015 Jan 02;350:g7647. (PMID: 25555855); Schizophr Res. 2020 Feb;216:97-103. (PMID: 31889574); Schizophr Res. 2013 Mar;144(1-3):146-50. (PMID: 23375943); Schizophr Res. 1999 May 25;37(2):123-32. (PMID: 10374648); BMJ. 2016 Oct 12;355:i4919. (PMID: 27733354); NPJ Schizophr. 2018 Oct 3;4(1):20. (PMID: 30282970); World Psychiatry. 2011 Oct;10(3):200-4. (PMID: 21991279); Am J Psychiatry. 2001 Feb;158(2):295-302. (PMID: 11156814); BMJ. 2019 Aug 28;366:l4898. (PMID: 31462531); Int J Psychophysiol. 2016 Jul;105:17-25. (PMID: 27117136); Arch Gen Psychiatry. 2001 Jun;58(6):590-6. (PMID: 11386989); Prim Care Companion J Clin Psychiatry. 2009;11(2):53-67. (PMID: 19617934); J Clin Psychiatry. 2010 Jan;71(1):14-25. (PMID: 19778496); Schizophr Bull. 2015 Mar;41 Suppl 2:S396-407. (PMID: 25548386); J Psychopharmacol. 2017 Apr;31(4):397-405. (PMID: 28347257); Psychiatry Res. 2018 Jun;264:398-403. (PMID: 29679842) |
| Contributed Indexing: | Keywords: MENTAL HEALTH; PSYCHIATRY; Personality disorders; Schizophrenia & psychotic disorders; Systematic Review |
| Entry Date(s): | Date Created: 20231117 Date Completed: 20231127 Latest Revision: 20240122 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10660957 |
| DOI: | 10.1136/bmjopen-2023-075140 |
| PMID: | 37977859 |
| Database: | MEDLINE |
Journal Article